Week in Review: Shanghai United Imaging Raises $500 Million in Series A; Zai Lab will IPO Next Week

Deals and Financings   Shanghai United Imaging Healthcare, which makes high-end medical imaging machines, closed a $500 million A financing at a $5 billion valuation; Shanghai Fosun Pharma signed a $106 million deal with Palatin for China rights to a female sexual desire disorder treatment; Harbour BioMed, a China-US biopharma, closed an $81 million agreement with Korea 's HanAll Biopharma to develop two of HanAll's novel biologics in China ; Wellem raised $30 million in a Series B Round to expand its network of franchised private pediatric clinics in China ; Suzhou Basecare Medical Device closed a $15.3 million B financing for its assisted reproduction diagnostic products; Ennovabio, a Shanghai pharma developing a brain cancer candidate, raised $10 million in a pre-A funding; Spineology of St. Paul, Minnesota announced a $5 million investment from Hermed Capital of Shanghai for its novel spinal devices; China Resources Holdings invested $4.6 million in Converd Company, a Hangzhou company developing oncolytic virus products; Grid Therapeutics of Durham, North Carolina completed an A financing from Singapore 's Longview to develop its cancer immunotherapy; HitGen. the Chengdu-Houston lead-generation CRO, signed a deal to discover novel drug leads for Japan 's Takeda Pharma. Stock Symbols: (SHA: 600196.SH; HK: 02196) (NYSE MKT: PTN) Share this with colleagues: // //